Best lymphoma treatmwnts

The short version: for most lymphomas, the best treatment depends on the exact type and stage, and the evidence for the most common regimen is stronger than for most vaccines, but the long-term immune consequences are barely studied.

For the most common aggressive lymphoma, diffuse large B-cell lymphoma (DLBCL), the standard is R-CHOP: rituximab plus a four-drug chemotherapy cocktail. The GELA LNH-98.5 trial, a randomized multicenter study of 328 patients aged 60-80, showed that adding rituximab to CHOP raised the complete response rate from 60% to 76% and improved 1-year overall survival from 68% to 83% [6]. A real-world Swedish study of 280 patients aged 80 and older confirmed that R-CHOP roughly doubled 2-year survival compared to CHOP alone, from about 29% to 63% [1]. The RICOVER-60 trial in 1,222 elderly patients found that six cycles of R-CHOP-14 (given every two weeks) produced a 3-year overall survival of 78%, compared to 68% with CHOP alone [5]. These are hard clinical endpoints, not surrogate markers, and the trials were not funded by a single manufacturer in the way vaccine trials typically are.

For Hodgkin lymphoma, the picture is more layered. The ECHELON-1 trial of 1,334 patients with stage III or IV disease found that brentuximab vedotin plus AVD chemotherapy improved 2-year modified progression-free survival to 82% versus 77% with standard ABVD [4]. But brentuximab vedotin carries a high rate of peripheral neuropathy (67% vs 43% with ABVD) and neutropenia (58% vs 45%) [4]. For relapsed or refractory Hodgkin lymphoma, anti-CD30 CAR-T cell therapy after fludarabine-based lymphodepletion produced a 72% overall response rate and 59% complete responses in a phase I/II trial of 32 heavily pretreated patients, with 1-year overall survival of 94% [3]. PD-1 inhibitors like nivolumab and pembrolizumab also show response rates around 69% in relapsed disease [2].

What is missing from this evidence is any serious study of long-term immune consequences. Chemotherapy and immunotherapy both disrupt the immune system, but the trials track cancer outcomes, not immune repertoire diversity, not reactivation of latent viruses, not long-term infection risk. The R-CHOP trials report toxicity during treatment but do not follow patients for years to measure whether the immune system ever fully recovers. The CAR-T and checkpoint inhibitor studies are even shorter. A treatment that saves your life from lymphoma can still leave you with a permanently altered immune system, and the published evidence does not tell you how often that happens or what it means.

My call: for DLBCL, R-CHOP is the best-supported option with real survival data from multiple randomized trials. For Hodgkin lymphoma, brentuximab-based regimens and CAR-T therapy offer meaningful benefit for relapsed disease, but the toxicity is substantial and the long-term immune effects are unstudied. Confidence: moderate.